表紙
市場調查報告書

藥物分析:Bavencio

Bavencio

出版商 Datamonitor Healthcare 商品編碼 603909
出版日期 內容資訊 英文 86 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Bavencio Bavencio
出版日期: 2019年03月06日內容資訊: 英文 86 Pages
簡介

本報告提供PD-L1蛋白質為標的之完全人型單株抗體 (MAb) 、Bavencio 的相關調查,主要國家/地區的銷售額成果與預測,各疾病的藥物評估、SWOT分析,及藥物簡介等。

  • 產品簡介
  • 摘要整理
  • Bavencio:頭頸癌
  • Bavencio:卵巢癌
  • Bavencio:膀胱癌
  • Avelumab:腎細胞癌 (RCC)
  • Avelumab:非小細胞肺癌 (NSCLC)
  • Avelumab:胃癌

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Bavencio: Renal cell carcinoma (RCC)
    • Bavencio: NHL: Diffuse large B-cell lymphoma (DLBCL)
    • Bavencio: Non-small cell lung cancer (NSCLC)
    • Bavencio: Gastric cancer
    • Bavencio: Head and neck cancer
    • Bavencio: Ovarian cancer
    • Bavencio: Bladder cancer

LIST OF FIGURES

  • Figure 1: Bavencio for RCC - SWOT analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Bavencio for RCC
  • Figure 3: Datamonitor Healthcare's drug assessment summary of Bavencio for RCC
  • Figure 4: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 5: Bavencio for diffuse large B-cell lymphoma - SWOT analysis
  • Figure 6: Datamonitor Healthcare's drug assessment summary for Bavencio in diffuse large B-cell lymphoma
  • Figure 7: Datamonitor Healthcare's drug assessment summary for Bavencio in diffuse large B-cell lymphoma
  • Figure 8: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 9: Bavencio for non-small cell lung cancer - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary for Bavencio in non-small cell lung cancer
  • Figure 11: Datamonitor Healthcare's drug assessment summary for Bavencio in non-small cell lung cancer
  • Figure 12: Bavencio sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 13: Bavencio for gastric cancer - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 16: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 17: Bavencio for head and neck cancer - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 20: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 21: Bavencio for ovarian cancer - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment of Bavencio for ovarian cancer
  • Figure 23: Datamonitor Healthcare's drug assessment of Bavencio for ovarian cancer
  • Figure 24: Bavencio for urothelial bladder cancer - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer

LIST OF TABLES

  • Table 1: Bavencio drug profile
  • Table 2: Bavencio Phase III data in RCC
  • Table 3: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 4: Bavencio drug profile
  • Table 5: Bavencio ongoing pivotal trial in diffuse large B-cell lymphoma
  • Table 6: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 7: Bavencio drug profile
  • Table 8: Bavencio Phase III trials in non-small cell lung cancer
  • Table 9: Bavencio Phase III trial data in non-small cell lung cancer
  • Table 10: Bavencio early-phase data in non-small cell lung cancer
  • Table 11: Bavencio sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 12: Bavencio patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 13: Bavencio drug profile
  • Table 14: Bavencio Phase III trials in gastric cancer
  • Table 15: Bavencio Phase III trial data in gastric cancer
  • Table 16: Bavencio early-phase data in gastric cancer
  • Table 17: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 18: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 19: Bavencio drug profile
  • Table 20: Bavencio Phase III trials in head and neck cancer
  • Table 21: Bavencio early-phase data in head and neck cancer
  • Table 22: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 23: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 24: Bavencio drug profile
  • Table 25: Bavencio Phase III trials in ovarian cancer
  • Table 26: Overview of Phase I data for Bavencio in ovarian cancer
  • Table 27: Bavencio drug profile
  • Table 28: Bavencio pivotal trial data in urothelial bladder cancer
  • Table 29: Bavencio ongoing late-phase trials in urothelial bladder cancer
Back to Top